Side-by-side · Research reference

Melanotan-IIvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED9/43 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

Melanotan-II

Testagen

Primary target

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Testicular tissue; proposed nuclear DNA interaction

Pathway

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

Melanotan-II

Testagen

Loading phase

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

—

Maintenance

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

—

Frequency

Daily during loading; 1–2× per week maintenance

Once daily or alternate days

Lower / starter dose

0.1 mg / day

Conservative starter — assess tolerability for nausea.

—

Evidence basis

Phase 1 + anecdotalDorr 1996

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water; protect from light

Sterile water or bacteriostatic saline

Timing

Evening preferred (24h tan-development cycle)

—

Half-life

~1 hour plasma; effects on melanocytes persist days

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

04Side Effects & Safety

Parameter

Melanotan-II

Testagen

Nausea

Common, especially loading phase

—

Flushing

Common transient

—

Spontaneous erection

Common in men — MC4R cross-effectDorr 1996

—

Increased mole / freckle pigmentation

Existing moles darken; new lesions possible

—

Melanoma risk

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

—

Appetite suppression

MC4R-mediated; mild

—

Pregnancy / OB

Contraindicated

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Testagen

·Active testicular malignancy

Relative Contraindications

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

Melanotan-II

Testagen

1. Reconstitution

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

SQ — abdomen. Rotate sites.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

29–31G insulin syringe.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.